{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:13:53Z","timestamp":1790165633096,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-17\\u20130026CE"],"award-info":[{"award-number":["ANR-21-17\\u20130026CE"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["ANR-10-IDEX-0002"],"award-info":[{"award-number":["ANR-10-IDEX-0002"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.autrev.2025.103817","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T17:54:21Z","timestamp":1745171661000},"page":"103817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autophagy in myositis, a dysregulated pathway, and a target for therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"A.S.","family":"Kamalanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Talamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylviane","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103817_bb0005","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2025.103817_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2025.103817_bb0020","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.clinph.2015.12.011","article-title":"Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment","volume":"127","author":"Needham","year":"2016","journal-title":"Clin Neurophysiol Off J Int Fed Clin Neurophysiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103644","article-title":"Inclusion body myositis: correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy","volume":"23","author":"Brady","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0035","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/rheumatology\/kead154","article-title":"Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature","volume":"62","author":"Demortier","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103817_bb0040","doi-asserted-by":"crossref","first-page":"1255540","DOI":"10.3389\/fimmu.2023.1255540","article-title":"Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array","volume":"14","author":"Kuzumi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/0004-282x-anp-2022-s131","article-title":"Inflammatory myopathies: an update for neurologists","volume":"80","author":"Silva","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2025.103817_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102257","article-title":"Current and new targets for treating myositis","volume":"65","author":"Moghadam-Kia","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103817_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/BOR.0b013e3283319265","article-title":"Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis","volume":"21","author":"Henriques-Pons","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0065","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0070","article-title":"Polymyositis and dermatomyositis - challenges in diagnosis and management","volume":"2","author":"Yang","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2025.103817_bb0075","article-title":"Scleromyositis: a distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis","volume":"13","author":"Giannini","year":"2022","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.autrev.2025.103817_bb0080","first-page":"00005","article-title":"Emerging mechanisms and therapeutics in inflammatory muscle diseases","volume":"S0165-6147","author":"Wischnewski","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2025.103817_bb0085","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: updates on evaluation and treatment","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2025.103817_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2020.10.014","article-title":"Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis","volume":"51","author":"Gupta","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103817_bb0095","doi-asserted-by":"crossref","first-page":"1127657","DOI":"10.3389\/fmed.2023.1127657","article-title":"Renal injury, biomarkers, and myositis, an understudied aspect of disease: prospective study in the MyoCite cohort","volume":"10","author":"Conticini","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/BOR.0000000000000957","article-title":"Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies","volume":"35","author":"Choi","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2025.103817_bb0110","article-title":"Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103817_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0125","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103817_bb0130","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103817_bb0135","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103817_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JND-140054","article-title":"Diagnostic utility of auto-antibodies in inflammatory muscle diseases","volume":"2","author":"Allenbach","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2025.103817_bb0145","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of Anti-CCAR1 autoantibodies with decreased Cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2025.103817_bb0150","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/art.42512","article-title":"Autoantibodies recognizing specificity protein 4 co-occur with anti-transcription intermediary factor 1 and are associated with distinct clinical features and Immunogenetic risk factors in juvenile myositis","volume":"75","author":"Sherman","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2025.103817_bb0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.bor.0000434673.85515.89","article-title":"The spectrum of statin myopathy","volume":"25","author":"Mohassel","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0160","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1083\/jcb.200804077","article-title":"Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy","volume":"183","author":"Cowling","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2025.103817_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101767","article-title":"Autoantibodies: pathogenic or epiphenomenon","volume":"36","author":"Galindo-Feria","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12889","article-title":"Icos gene disruption in non-obese diabetic mice elicits myositis associated with anti-troponin T3 autoantibodies","volume":"49","author":"Bourdenet","year":"2023","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103204","article-title":"Two novel anti-aminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase","volume":"21","author":"Muro","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0180","doi-asserted-by":"crossref","first-page":"1439807","DOI":"10.3389\/fimmu.2024.1439807","article-title":"Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940122","article-title":"Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: does the endoplasmic reticulum stress response have a role?","volume":"13","author":"Corona-Sanchez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0195","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.autrev.2012.10.009","article-title":"Antibody-mediated catalysis: induction and therapeutic relevance","volume":"12","author":"Mahendra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaut.2011.05.007","article-title":"Autoantibodies with enzymatic properties in human autoimmune diseases","volume":"37","author":"Wootla","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103817_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103310","article-title":"Autoantibodies targeting G protein-coupled receptors: an evolving history in autoimmunity. Report of the 4th international symposium","volume":"22","author":"Cabral-Marques","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41537-021-00143-6","article-title":"DNA hydrolysing IgG catalytic antibodies: an emerging link between psychoses and autoimmunity","volume":"7","author":"Ramesh","year":"2021","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.autrev.2025.103817_bb0215","doi-asserted-by":"crossref","first-page":"27970","DOI":"10.1038\/s41598-024-75200-y","article-title":"Occurrence of protease-like catalytic activity in the polyclonal IgG in schizophrenia and bipolar disorder","volume":"14","author":"Ramesh","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13550-017-0348-2","article-title":"Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy","volume":"7","author":"Th\u00f8gersen","year":"2017","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.autrev.2025.103817_bb0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/BOR.0000000000000960","article-title":"MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives","volume":"35","author":"Pettorossi","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0230","doi-asserted-by":"crossref","first-page":"228","DOI":"10.21037\/atm-22-70","article-title":"Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0235","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm-21-475","article-title":"Narrative review of autoantibodies in idiopathic inflammatory myopathies","volume":"11","author":"Liu","year":"2023","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate Mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2025.103817_bb0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","article-title":"Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics","volume":"52","author":"Moghadam-Kia","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0250","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19886494","article-title":"New insights into the treatment of myositis","volume":"12","author":"Glaubitz","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2025.103817_bb0255","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/rheumatology\/keae096","article-title":"Where are we now in biologic drugs for myositis?","volume":"63","author":"Neves","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103817_bb0260","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103817_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/art.43066","article-title":"Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial","author":"Aggarwal","year":"2025","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103817_bb0270","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2025.103817_bb0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0280","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2025.103817_bb0285","first-page":"460","article-title":"Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab","volume":"42","author":"Chua","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2025.103817_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0300","doi-asserted-by":"crossref","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0305","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.autrev.2025.103817_bb0310","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103817_bb0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12964-024-01714-7","article-title":"The role of KLRG1: a novel biomarker and new therapeutic target","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.autrev.2025.103817_bb0320","doi-asserted-by":"crossref","first-page":"1382728","DOI":"10.3389\/fimmu.2024.1382728","article-title":"Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0325","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kead404","article-title":"Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients","volume":"63","author":"Beckett","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103817_bb0330","first-page":"911","article-title":"Antibody therapies in autoimmune inflammatory myopathies: promising treatment options","volume":"19","author":"Zeng","year":"2022","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.autrev.2025.103817_bb0335","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.0000000000011628","article-title":"Challenges for treatment trials of inclusion body myositis","volume":"96","author":"Roy","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103817_bb0340","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.autrev.2017.03.001","article-title":"Animal models in idiopathic inflammatory myopathies: how to overcome a translational roadblock?","volume":"16","author":"Afzali","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0345","first-page":"117","article-title":"Experimental autoimmune myositis in SJL\/J mice","volume":"68","author":"Rosenberg","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0165-5728(01)00377-0","article-title":"Experimental allergic myositis in SJL\/J mouse. Reappraisal of immune reaction based on changes after single immunization","volume":"119","author":"Matsubara","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/25785826.2022.2137968","article-title":"Murine models of idiopathic inflammatory myopathy","volume":"46","author":"Konishi","year":"2023","journal-title":"Immunol Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0360","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1346-8138.17142","article-title":"Murine models of idiopathic inflammatory myopathies","volume":"51","author":"Okiyama","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0365","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1113\/JP286534","article-title":"Nrf2 deficiency in muscle attenuates experimental autoimmune myositis-induced muscle weakness","volume":"602","author":"Himori","year":"2024","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.638983","article-title":"The role of autophagy in skeletal muscle diseases","volume":"12","author":"Xia","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0375","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1002\/art.27625","article-title":"Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis","volume":"62","author":"Sugihara","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103817_bb0380","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.39592","article-title":"Interferon-\u03b3, but not Interleukin-4, suppresses experimental polymyositis","volume":"68","author":"Yoshihashi-Nakazato","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2025.103817_bb0385","doi-asserted-by":"crossref","first-page":"17958","DOI":"10.1038\/s41598-018-36395-z","article-title":"Patients with anti-Jo1 antibodies display a characteristic IgG fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies","volume":"8","author":"Fernandes-Cerqueira","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0390","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","article-title":"Role of jo-1 in the Immunopathogenesis of the anti-synthetase syndrome","volume":"17","author":"Ascherman","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0395","doi-asserted-by":"crossref","first-page":"1238221","DOI":"10.3389\/fimmu.2023.1238221","article-title":"Antigen-driven T cell-macrophage interactions mediate the interface between innate and adaptive immunity in histidyl-tRNA synthetase-induced myositis","volume":"14","author":"Reay","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.55563\/clinexprheumatol\/pp0oso","article-title":"The role of protein aggregation in the pathogenesis of inclusion body myositis","volume":"40","author":"Snedden","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41584-018-0138-x","article-title":"TDP-43 in the muscles: friend or foe?","volume":"15","author":"McHugh","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0410","doi-asserted-by":"crossref","first-page":"eadp5730","DOI":"10.1126\/scitranslmed.adp5730","article-title":"Seeding-competent TDP-43 persists in human patient and mouse muscle","volume":"16","author":"Lynch","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0415","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1073\/pnas.97.16.9209","article-title":"Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies","volume":"97","author":"Nagaraju","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103817_bb0420","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/art.30530","article-title":"The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage","volume":"63","author":"Alger","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103817_bb0425","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/s41467-024-49460-1","article-title":"IFN\u03b3 causes mitochondrial dysfunction and oxidative stress in myositis","volume":"15","author":"Abad","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103817_bb0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mmr.2024.13378","article-title":"Selective protein degradation through chaperone-mediated autophagy: implications for cellular homeostasis and disease (review)","volume":"31","author":"Huang","year":"2025","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0435","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41556-024-01404-z","article-title":"Next questions in autophagy","volume":"26","author":"Cuervo","year":"2024","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.autrev.2025.103817_bb0440","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41581-023-00692-2","article-title":"The role of lysosomes in metabolic and autoimmune diseases","volume":"19","author":"Gros","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2025.103817_bb0445","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1750-3639.2009.00290.x","article-title":"Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation","volume":"19","author":"Askanas","year":"2009","journal-title":"Brain Pathol Zurich Switz"},{"key":"10.1016\/j.autrev.2025.103817_bb0450","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/nan.12038","article-title":"Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres","volume":"39","author":"Cacciottolo","year":"2013","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0455","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Mari\u00f1o","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.autrev.2025.103817_bb0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-pathmechdis-012419-032618","article-title":"Autophagy defects in skeletal myopathies","volume":"15","author":"Margeta","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.autrev.2025.103817_bb0465","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nan.12040","article-title":"Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis","volume":"39","author":"Girolamo","year":"2013","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2025.103817_bb0470","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.nmd.2016.12.009","article-title":"The role of p62\/SQSTM1 in sporadic inclusion body myositis","volume":"27","author":"Nakano","year":"2017","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.autrev.2025.103817_bb0475","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2353\/ajpath.2010.100050","article-title":"Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers","volume":"177","author":"Nogalska","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2025.103817_bb0480","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.neurobiolaging.2016.07.024","article-title":"Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis","volume":"47","author":"Gang","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.autrev.2025.103817_bb0485","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/BOR.0000000000000748","article-title":"Nonimmune mechanisms in idiopathic inflammatory myopathies","volume":"32","author":"Loredo Martinez","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0490","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3892\/mmr.2017.6693","article-title":"Potential role of autophagy in T-cell survival in polymyositis and dermatomyositis","volume":"16","author":"Shu","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2025.103817_bb0495","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/jcsm.13000","article-title":"Autophagy in muscle regeneration: potential therapies for myopathies","volume":"13","author":"Chen","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.autrev.2025.103817_bb0500","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tips.2023.11.005","article-title":"Pharmacological targets at the lysosomal autophagy\u2013NLRP3 inflammasome crossroads","volume":"45","author":"Bonam","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2025.103817_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103738","article-title":"Immunometabolic shifts in autoimmune disease: mechanisms and pathophysiological implications","volume":"24","author":"Chen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103817_bb0510","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.3390\/ijms241310675","article-title":"Inflammasome in skeletal muscle: NLRP3 is an inflammatory cell stress component in inclusion body myositis","volume":"24","author":"Kummer","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103817_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13672","article-title":"NLRP3 Inflammasome activation and altered Mitophagy are key pathways in inclusion body myositis","volume":"16","author":"Naddaf","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.autrev.2025.103817_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103332","article-title":"Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis","volume":"149","author":"Notarnicola","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103817_bb0525","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2025.103817_bb0530","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature11862","article-title":"Metabolism of inflammation limited by AMPK and pseudo-starvation","volume":"493","author":"O\u2019Neill","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103817_bb0535","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/15548627.2015.1017179","article-title":"Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide","volume":"11","author":"Macri","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.autrev.2025.103817_bb0540","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/cells9102328","article-title":"In vivo remodeling of altered autophagy-lysosomal pathway by a Phosphopeptide in lupus","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103817_bb0545","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.3390\/cells11233709","article-title":"The therapeutic effect of Phosphopeptide P140 attenuates inflammation induced by uric acid crystals in gout arthritis mouse model","volume":"11","author":"Galv\u00e3o","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103817_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102814","article-title":"Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases","volume":"128","author":"Retnakumar","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103817_bb0555","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.15252\/embj.201796697","article-title":"Molecular definitions of autophagy and related processes","volume":"36","author":"Galluzzi","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2025.103817_bb0560","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.2147\/JIR.S436147","article-title":"The role and mechanism of metformin in inflammatory diseases","volume":"16","author":"Lin","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103817_bb0565","doi-asserted-by":"crossref","first-page":"fs2","DOI":"10.1126\/scisignal.aaf1937","article-title":"Mystery solved: Trehalose kickstarts autophagy by blocking glucose transport","volume":"9","author":"Mardones","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.autrev.2025.103817_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.783416","article-title":"Clinical characteristics and Management of Patients with Clinical Amyopathic Dermatomyositis: a retrospective study of 64 patients at a tertiary dermatology department","volume":"8","author":"Tang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2025.103817_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074450","article-title":"Beneficial role of rapamycin in experimental autoimmune myositis","volume":"8","author":"Prevel","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103817_bb0580","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103817_bb0585","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.transproceed.2007.11.072","article-title":"Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus","volume":"40","author":"Kaposztas","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2025.103817_bb0590","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/zvffa0","article-title":"Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM functional rating scale","author":"Badrising","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175153","article-title":"Silibinin eliminates mitochondrial ROS and restores autophagy through IL6ST\/JAK2\/STAT3 signaling pathway to protect cardiomyocytes from doxorubicin-induced injury","volume":"929","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2025.103817_bb0600","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103817_bb0605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molimm.2023.05.005","article-title":"AXL-induced autophagy mitigates experimental autoimmune encephalomyelitis by suppressing microglial inflammation via the PI3K\/AKT\/mTOR signaling pathway","volume":"159","author":"Sun","year":"2023","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103817_bb0610","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.3390\/ijms241311212","article-title":"The role of autophagy and apoptosis in affected skin and lungs in patients with systemic sclerosis","volume":"24","author":"Spasovski","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103817_bb0615","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/annrheumdis-2024-eular.3718","article-title":"POS1061 VORINOSTAT as a dual inhibitor of type I IFN production and aberrant b cell: a novel therapeutic candidate for systemic lupus erythematosus","volume":"83","author":"Hirayama","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103817_bb0620","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-023-03181-w","article-title":"Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103817_bb0625","doi-asserted-by":"crossref","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A randomised, placebo-controlled study of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2025.103817_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbadis.2018.10.007","article-title":"mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+Gr1+ cells","volume":"1865","author":"Shi","year":"2019","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"10.1016\/j.autrev.2025.103817_bb0635","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/cells10092468","article-title":"An autophagy modulator peptide prevents lung function decrease and corrects established inflammation in murine models of airway allergy","volume":"10","author":"Daubeuf","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103817_bb0640","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaut.2018.08.009","article-title":"Autophagy: a new concept in autoimmunity regulation and a novel therapeutic option","volume":"94","author":"Bonam","year":"2018","journal-title":"J Autoimmun"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:06:24Z","timestamp":1762553184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":128,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1568997225000771"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103817","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autophagy in myositis, a dysregulated pathway, and a target for therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103817"}}